Drug Trial Radar · NCT03941548
Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata
Last checked: Nov 19, 2026Latest source record: Apr 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
66
Actual
Start
May 24, 2019
Primary completion
Apr 10, 2020
Study completion Apr 10, 2020
Sponsor
- Lead sponsor
- Concert PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- May 8, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata.
Conditions
- Alopecia Areata
Interventions
CTP-543Drug
Administered as 12 mg tablets.
CTP-543 Matching PlaceboDrug
Administered as tablets to aid treatment masking.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relative Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24Time frame: Baseline, Week 24
Locations
12 sites in 2 countries. Site status is shown where the registry gives one.
Colorado Center for Dermatology and Skin Surgery
Centennial, Colorado
ForCare Clinical Research
Tampa, Florida
The Indiana Clinical Trials Center, PC
Plainfield, Indiana
Massachusetts General Hospital
Boston, Massachusetts
Austin Institute for Clinical Research, Inc.
Pflugerville, Texas
SimcoDerm Medical and Surgical Dermatology Center
Barrie, Ontario, Canada
Guelph Dermatology Research
Guelph, Ontario, Canada
Dr Wei Jing Loo Medicine Professional Corporation
London, Ontario, Canada
Lynderm Research Inc.
Markham, Ontario, Canada
The Centre for Clinical Trials
Oakville, Ontario, Canada
Research Toronto
Toronto, Ontario, Canada
Innovaderm Research Inc.
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.